Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

Hormones and Cardiovascular Disease
Director: Pierre-Yves Scarabin

 

This review provides a summary of the association between hormonal contraceptives and cardiovascular events. Current use of third generation combined oral contraceptive (COC) or COC containing drospirenone or cyproterone increased the risk of venous thromboembolism compared with second generation pills. Non-oral route of ethinyl-estradiol administration (patch, vaginal ring) seems to be more thrombogenic than oral route. In contrast, low doses of both oral progestin contraceptives and intrauterine levonorgestrel may be safe with respect to the risk of venous thrombosis. Current use of COC increased the risk of myocardial infarction and ischemic stroke but this was not associated with the risk of hemorrhagic stroke. The risk of ischemic arterial disease among current users of second or third generation pill was similar. Newer generation formulations of COCs, as well as the non-oral hormonal contraceptive, do not seem to be safer than second generation hormonal contraceptives with respect to arterial disease.

© Esther 2019